Cutia Therapeutics (HKSE:02487) EPS (Basic) : HK$-1.51 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics EPS (Basic)?

Cutia Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was HK$-0.80. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.51.

Cutia Therapeutics's EPS (Diluted) for the six months ended in Dec. 2024 was HK$-0.80. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-1.51.

Cutia Therapeutics's EPS without NRI for the six months ended in Dec. 2024 was HK$-0.82. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -1.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cutia Therapeutics EPS (Basic) Historical Data

The historical data trend for Cutia Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics EPS (Basic) Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-1.29

-2.04

-10.50

-1.51

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial			-1.12	-17.33	-1.16	-0.71	-0.80

Cutia Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cutia Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-463.168	-	0)	/	307.193
	=	-1.51

Cutia Therapeutics's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-248.645	-	0)	/	309.655
	=	-0.80

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.51

Cutia Therapeutics (HKSE:02487) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cutia Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.

Executives

Zhang Lele	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Yf Dermatology Limited	2101 Beneficial owner
Yunfeng Capital Limited	2102 Investment manager
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines